Cancers, Vol. 15, Pages 430: Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma
Conclusions: The combination of ixazomib and G-CSF showed promising stem cell mobilizing activity in patients with MM prior to HDCT and ASCT. Future larger studies might further investigate the role of ixazomib in stem cell mobilization regimens for MM. (Source: Cancers)
Source: Cancers - January 9, 2023 Category: Cancer & Oncology Authors: Selina B ühler Dilara Akhoundova Barbara Jeker Myriam Legros Katja Seipel Michael Daskalakis Ulrike Bacher Thomas Pabst Tags: Article Source Type: research
Breast tumor metastasis following filgrastim administration due to the SDF-1/CXCR4 pathway
AbstractFilgrastim, a recombinant type of granulocyte-colony stimulating factor (G-CSF), has a high potential to manage chemotherapy-induced leukopenia. It can increase stromal cell-derived factor 1 (SDF-1) which may stimulate C-X-C chemokine receptor type 4 (CXCR4) to migrate bone marrow-derived stem/progenitor cells to the bloodstream. Here, we aimed to investigate in vitro and in vivo effects of filgrastim on cell migration, invasion, and metastasis. A lentivirus vector of the anti-CXCR4 receptor was first used for the CXCR4 knockout. Effects of filgrastim on cell proliferation and migration were then investigated on 4T...
Source: Medical Oncology - January 6, 2023 Category: Cancer & Oncology Source Type: research
Cancers, Vol. 14, Pages 6197: Real-World Use of Granulocyte-Colony Stimulating Factor in Patients with Breast Cancer from Alberta, Canada
Conclusions: Despite increasing G-CSF usage over time, an appreciable proportion of patients for whom G-CSF prophylaxis is recommended did not receive it. G-CSF use could be further optimized to align with supportive care clinical guidelines and reduce the impact of neutropenia and its associated complications. (Source: Cancers)
Source: Cancers - December 15, 2022 Category: Cancer & Oncology Authors: Philip Q. Ding Brandt J. Newcomer Winson Y. Cheung Tags: Article Source Type: research
A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices
ConclusionPatients receiving pegfilgrastim OBI had a lower incidence of FN compared with those receiving alternatives. The OBI was associated with improved adherence to and compliance with clinically recommended G-CSF prophylaxis. (Source: Supportive Care in Cancer)
Source: Supportive Care in Cancer - September 26, 2022 Category: Cancer & Oncology Source Type: research
Factors Associated with Absolute Neutrophil Count Dynamics and Docetaxel-Adryamicin-Cyclophosphamide (TAC) Chemotherapy Induced Neutropenia During Extended Filgrastim Administration in Breast Cancer Patients
CONCLUSION: CIN still occured in breast cancer patient receiving filgrastim primary prophylaxis regardless of age and neutropenia severity. Nadir as the lowest point of ANC should be noted as a pivotal milestone for ANC slope and recovery evaluation.PMID:36156473 (Source: Acta medica Indonesiana)
Source: Acta medica Indonesiana - September 26, 2022 Category: Internal Medicine Authors: Ami Ashariati Ugroseno Yudho Bintoro Merlyna Savitri Muhammad Noor Diansyah Putu Niken Ayu Amrita Pradana Zaky Romadhon Andi Yasmin Wijaya Winona May Hendrata Steven Sheng Looi Ahmad Amin Mahmudin Source Type: research
